Observation And Analysis Of The Effect Of Conbercept In The Treatment Of Neovascular Age-related Macular Degeneration With Different Regimens

Objective: To observe the effect of conbercept in the treatment of neovascular age-related macular degeneration(nAMD)with Treat and Extend(T&E)regimen and pro re nata(PRN)regimen,that follow-up of 12 months is required,and analyze the effect and drug injection times.And comparing the two regimens to provide reference for clinical medication scheme of conbercept.Methods: 29 patients with newly diagnosed nAMD were randomly divided into T&E group(14 eyes)and the PRN group(15 eyes),observe and record the indexes that before treated and after treatment for 6 months,12 months,the indexes including best corrected visual acuity(BCVA),central retinal thickness(CRT)and safety of intravitreal injection,observing the indexes change and injection times,then analyze the differences of the two groups.Results: There is no significant difference in baseline characteristics(eye sex,age,sex,BCVA,CRT)between the T&E group(n=14)and thePRN group(n=15).Before treatment,BCVA(logMAR)in the T&E group was 0.69±0.30,and it was 0.45±0.31 at 6 months and 0.43±0.32 at 12 months respectively,with statistically significant differences(P <0.05),and BCVA in PRN group was 0.87±0.36 when untreated,0.68±0.35 at 6 months and 0.62±0.37 at 12 months while the difference is statistically significant(P < 0.05).At 6 months of treatment,BCVA in T&E group and PRN group improved by 0.25±0.15 and 0.19±0.19 respectively,with no statistically significant difference(P > 0.05).At 12 months of treatment,BCVA in T&E group and PRN group improved by 0.26±0.16 and0.24±0.22 respectively,with no statistically significant difference(P >0.05).Before treatment,the CRT of T&E group was(398.50±111.96)?m while it was(264.57±92.30)?m at 6 months and(226.35±54.53)?m at 12 months under therapy,with statistically significant difference(P < 0.05).Before treatment,the CRT of PRN group was(470.60±152.29)?m,when applying treatment it was(360.20±139.75)?m at 6 months and(316.13±115.37)?m at 12 months,with statistically significant difference(P < 0.05).At 6 months of treatment,the CRT in T&E group and PRN group decreased(133.93±55.30)?m and(110.40±35.97)?m respectively,with a statistical difference(P < 0.05).At 12 months of treatment,the CRT in T&E group and PRN group decreased(172.14±77.39)?m and(155.13±49.82)?m respectively,with a statistical difference(P < 0.05).The injection numbers of T&E group and PRN group were 5.00 times and(3.93±0.46)times at 6 months of treatment,and 7.00 times and(5.86±0.52)times at 12 months of treatment,respectively.During the whole treatment,subconjunctival hemorrhage occurred in 2 patients(1 in T&E group and 1in PRN group),which were absorbed spontaneously.There was no significant difference in intraocular pressure between the two groups before and after treatment(P >0.05).No adverse events such as endophthalmitis,aggravated lens opacity,vitreous hemorrhage,or cardiovascular and cerebrovascular accidents occurred in the two groups.Conclusion: In the treatment of nAMD with intravitreal injection of conbercept,both T&E regimen and PRN regimen can effectively improve BCVA and reduce CRT.T&E regimen shows a similar improvement in visual acuity at 6 months and 12 months compared with PRN regimen,but the reduce in CRT with T&E is superior to PRN at 6 months and 12 months.The injection numbers of T&E regimen at 6 months and 12 months is relatively higher than that of PRN regimen,but no monthly follow-up was required.The T&E program is expected to provide better treatment outcomes for nAMD patients.